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Care (IBH-PC) to improve patient-centered
outcomes in adults with multiple chronic
medical and behavioral health conditions:
study protocol for a pragmatic cluster-
randomized control trial
Abigail M. Crocker1* , Rodger Kessler2,3, Constance van Eeghen1, Levi N. Bonnell1, Ryan E. Breshears4,
Peter Callas1, Jessica Clifton1, William Elder5, Chet Fox6, Sylvie Frisbie1, Juvena Hitt1, Jennifer Jewiss1, Roger Kathol7,
Kelly Clark/Keefe1, Jennifer O’Rourke-Lavoie1, George S. Leibowitz8, C. R. Macchi2, Mark McGovern9, Brenda Mollis10,
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Terry Stancin17, Kurt C. Stange18, Kari A. Stephens10, Kathryn Teng17, Elizabeth Needham Waddell19 and
Benjamin Littenberg1
Abstract
Background: Chronic diseases that drive morbidity, mortality, and health care costs are largely influenced by
human behavior. Behavioral health conditions such as anxiety, depression, and substance use disorders can often
be effectively managed. The majority of patients in need of behavioral health care are seen in primary care, which
often has difficulty responding. Some primary care practices are providing integrated behavioral health care (IBH),
where primary care and behavioral health providers work together, in one location, using a team-based approach.
Research suggests there may be an association between IBH and improved patient outcomes. However, it is often
difficult for practices to achieve high levels of integration. The Integrating Behavioral Health and Primary Care study
responds to this need by testing the effectiveness of a comprehensive practice-level intervention designed to
improve outcomes in patients with multiple chronic medical and behavioral health conditions by increasing the
practice’s degree of behavioral health integration.
Methods: Forty-five primary care practices, with existing onsite behavioral health care, will be recruited for this
study. Forty-three practices will be randomized to the intervention or usual care arm, while 2 practices will be
considered “Vanguard” (pilot) practices for developing the intervention. The intervention is a 24-month supported
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practice change process including an online curriculum, a practice redesign and implementation workbook, remote
quality improvement coaching services, and an online learning community. Each practice’s degree of behavioral
health integration will be measured using the Practice Integration Profile. Approximately 75 patients with both
chronic medical and behavioral health conditions from each practice will be asked to complete a series of surveys
to measure patient-centered outcomes. Change in practice degree of behavioral health integration and patient-
centered outcomes will be compared between the two groups. Practice-level case studies will be conducted to
better understand the contextual factors influencing integration.
Discussion: As primary care practices are encouraged to provide IBH services, evidence-based interventions to
increase practice integration will be needed. This study will demonstrate the effectiveness of one such intervention
in a pragmatic, real-world setting.
Trial registration: ClinicalTrials.gov NCT02868983. Registered on August 16, 2016.
Keywords: Behavioral health, Primary care, Multiple chronic conditions, Pragmatic trials, Randomized control trial
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Introduction
Background and rationale {6a}
The chronic diseases that drive the majority of
morbidity, mortality, and health care costs in America
and around the globe are largely influenced by human
behavior. Tobacco use, poor diet, alcohol and substance
use disorders, and physical inactivity together account
for 38% of all deaths in the USA [1]. Insomnia, anxiety,
depression, stress, and non-adherence to recommended
treatment contribute additional morbidity and mortality.
The presence of both chronic medical and behavioral
health conditions drive poorer outcomes and higher
costs than either alone [2, 3].
Behavioral Health Care (BH) is a short-hand term
representing a wide variety of services that have often
been physically, operationally, and even ideologically iso-
lated from one another. The working definition of BH
for this study (modified from Baird, 2014 [4]) is mental
health care, substance use disorder care, health behavior
change, and attention to family and other psychosocial
factors that affect a person or a family unit. Conditions
addressed as part of BH include depression, anxiety,
stress, insomnia, overeating, inactivity, smoking, medica-
tion non-adherence, chronic pain, problem drinking,
substance use disorder, and family distress.
Behavioral health conditions can often be effectively
managed, resulting in improved outcomes for patients,
their families and the health care system. Several
psychological and behavioral techniques, including
Cognitive Behavioral Therapy [5–8] and the IMPACT
collaborative care model [9], improve outcomes, best
demonstrated for depression.
The majority of patients in need of BH are seen in
primary care, but that setting has difficulty responding
to the full set of needs. Forty percent of primary care
patients have BH needs and the need is even higher
among those with chronic medical conditions [10].
Although some primary care providers (PCPs) are
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skilled and effective at delivering BH [11], many do not
have the training, time, or inclination [12]. High-quality
BH is the single most difficult area of medical care for
patients to access [13] and nearly 70% of the more ser-
ious behavioral health conditions in primary care are
neither assessed nor treated [14].
The traditional approach to delivering BH in much of
the world is for PCPs to refer patients to specialists
(psychiatrists, psychologists, counselors, and therapists)
outside the primary care setting. Unfortunately, high-
quality services are often not available, the referral
process is challenging, and treatment initiation rates are
low, in part due to the perceived stigma of seeing a men-
tal health specialist [15–17]. Communication between
mental health specialists and PCPs is often hampered by
confidentiality concerns, time constraints, legal re-
straints, transportation barriers, and traditional practice
habits. Fifty percent to 90% of primary care referrals
made to out-of-office mental health practitioners fail to
result in an appointment [18]. Of those patients who do
schedule an appointment, most never initiate care [19].
When care is initiated, most of that care is not evidence-
supported [20].
In response to these barriers, many primary care
practices have instituted co-located services in which a
Behavioral Health Provider (BHP) such as a psychologist
or counselor and PCP deliver care in the same location
[21]. This model eliminates some of the barriers to ac-
cess, but the BHP often operates independently from the
PCPs with separate hours, space, appointment systems,
and medical records. Often, there is little communica-
tion or shared records between the two disciplines.
There is little evaluation of such interventions [22].
An alternative approach to delivering BH for primary
care patients is Integrated Behavioral Health Care (IBH)
in which the BHP is a full member of the practice who
shares workspace, infrastructure, records and support
systems, participates fully in the life of the practice, and
collaborates closely with PCPs in patient assessment and
management. Beyond co-location, IBH includes support
for population management, protocol-driven evidence-
supported care, guideline-based external referral, use of
brief visits, systematic needs identification, and practice-
wide approaches to patient engagement.
The working definition of IBH (adapted from Korsen,
2013 [23]) for this study is the care a patient receives
when PCPs and BHPs use a collaborative system of care,
rather than focusing on separate approaches. Its goals
are better and more efficient care of mental health
conditions, substance use disorders, and chronic medical
illnesses; better recognition and management of life
stressors, crises, and stress-related physical symptoms;
improved health behaviors; and more thoughtful and ef-
ficient health care utilization. Research suggests there
may be an association between IBH and patient out-
comes [24].
For primary care practices to effectively shift from co-
located services to IBH, a supported practice change
process is required [4]. While IBH checklists identifying
integration elements exist [23, 25], a comprehensive
intervention that systematically combines practice re-
design with quality improvement (QI) coaching, provider
and staff education, and collaborative learning does not.
The Integrating Behavioral Health and Primary Care
study (IBH-PC) responds to this need by testing the ef-
fectiveness of a comprehensive practice-level interven-
tion (the IBH-PC toolkit) designed to improve outcomes
in patients with multiple chronic medical and behavioral
health conditions by increasing a practice’s degree of be-
havioral health integration. We sought to deploy the
toolkit in a broad array of primary care practices and
test its impact on patient functional status as well as the
practices’ level of integration. We chose a pragmatic ran-
domized trial design to allow our analysis and conclu-




Increased integration of evidence-supported behavioral
health and primary care, compared to simple co-location
of providers, will improve patient-centered outcomes in
patients with multiple chronic medical and behavioral
health conditions.
Research questions
1. Does using the IBH-PC toolkit, a practice-level
intervention, affect patient-centered outcomes in
adults with multiple chronic medical and behavioral
health conditions?
2. Does using the IBH-PC toolkit affect the degree of
practice-level behavioral health care integration in
primary care practices?
3. What factors support or impede successful
integration of behavioral health care into primary
care practices?
4. What are the costs of implementing the IBH-PC
toolkit?
Trial design {8}
The IBH-PC study is a two-arm, parallel, superiority,
pragmatic, cluster-randomized trial that treats patients
as the units of analysis clustered within practices that
are the units of intervention. Practices are assigned in a
1:1 allocation ratio.
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Methods: Participants, interventions, and
outcomes
Study setting {9}
The IBH-PC study takes place in 45 primary care
practices across the United States (Fig. 1). Practices
represent a diverse distribution of geographic regions,
population densities (urban vs. rural), patient popula-
tion size, specialty (family vs. internal medicine), com-
munity health centers, federally qualified health
centers, nonprofit and for-profit organizations, resi-




Primary care practices are eligible to participate if they:
 Have at least one PCP and at least one BHP onsite
(co-located),
 Have at least 0.5 full-time equivalent BHPs licensed
to practice independently,
 Commit to maintaining onsite BHP for the duration
of the study,
 Provide the research team with access to electronic
medical records (EMRs) to identify patients with
specific medical and behavioral health conditions for
recruitment,
 Are willing to complete survey instruments
periodically throughout the study, and
 Are willing to be randomized to either the active or
control arm.
For practices with more than 10% of their revenue
generated by Medicare, at least one BHP per practice
must be eligible to bill Medicare. Practices are ineligible
if they are already undergoing, or plan to undergo,
another QI initiative similar to the IBH-PC intervention
or if they already have an advanced level of BH integra-
tion as evidenced by a total Practice Integration Profile
score (PIP) above 75. The PIP is a survey of 30 items
completed by primary care providers and staff about
their own practice used to measure practice level inte-
gration [26, 27].
Study patient participants
Patients are eligible to participate if they:
Fig. 1 Integrating Behavioral Health and Primary Care (IBH-PC) clinical sites
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 Are at least 18 years old,
 Are an active patient of a participating study
practice as evidenced by at least two visits in a
period of 24 months for any purpose, including at
least one in the most recent 6 months,
 Are willing to complete three surveys over 2 years,
and
 Have both an eligible chronic medical condition and
an eligible chronic behavioral health condition, or at
least three eligible chronic medical conditions.
Eligible chronic medical conditions include arthritis;
obstructive lung disease including emphysema,
chronic bronchitis, or asthma; non-gestational dia-
betes; and heart disease manifested as heart failure
or hypertension. Eligible behavioral health condi-
tions include mood disorder (anxiety or depression),
chronic pain (including headache, migraine, neural-
gia, fibromyalgia, or chronic musculoskeletal pain),
insomnia, irritable bowel syndrome, and substance
misuse (substance use disorder, tobacco use, or
problem drinking).
To determine patient eligibility, medical records are
reviewed for a period of 24 months with the most recent
date being within 12 months of the study start at each
practice. Within this period, evidence of age, minimum
number of visits, and medical and behavioral health
conditions will be determined.
Evidence of medical conditions may take the form of a
specific diagnosis on a problem list. Evidence of diabetes
may also be indicated by 3months of insulin or other
diabetes medications (excepting metformin which is not
specific to diabetes) or any hemoglobin A1C value
greater than 6.4%. Evidence of heart disease may also be
indicated by 3 months of cardiac medications specific to
hypertension or heart failure (excepting beta-blockers
and other medications with broader indications), or 3
sequential blood pressure measurements with mean
systolic pressure > 140mmHg or mean diastolic pres-
sure > 95 mmHg.
Evidence of a behavioral health condition may take the
form of a specific diagnosis on a patient’s problem list, 3
months of certain medications used for behavioral
conditions (antidepressants, anxiolytics, opioids,
antineuropathic agents, agents for alcohol use disorder
or smoking cessation, etc.), or persistent failure to attain
physiologic control of a medical problem evidenced as
systolic blood pressure > 165 mmHg for 3 months or
more or A1C > 9% for 6 months or more.
Who will take informed consent? {26a}
Eligible patient participants are identified by review of
EMRs in each participating primary care practice [28].
Acting as trusted third party, the DARTNet Institute
[29] reviews the EMR data, identifies potential patient
participants, and offers participation.
Eligible patients are mailed a letter describing the
purpose of the study and that, if they choose to
participate, they are requested to complete a brief set of
surveys at three timepoints via web, paper, or phone.
The letter also describes the process to opt-out as well
as provides a phone number to call for more informa-
tion on the study. The DARTNet Institute follows-up
the letters with phone calls to eligible patients. Consent
is administered and documented by phone, paper, or via
web at the completion of the baseline set of surveys. Par-
ticipating patients provide consent to link their EMRs to
survey data and may discontinue participation at any
time. All study materials are available in both Spanish
and English.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
The study consent process includes permission for
additional analyses of collected data. No biological
specimens are collected.
Interventions
Explanation of the choice of comparators {6b}
The active comparator (the intervention) is the use of
the IBH-PC toolkit to support a practice-level change
process. Use of the IBH-PC toolkit is intended to in-
crease the delivery of highly integrated behavioral health
and primary care, which is hypothesized to result in
improved patient outcomes. The control comparator is
co-location of a behavioral health provider within or ad-
jacent to the primary care practice (at the same street
address), without additional integration [12]. Co-location
was chosen as the control comparator as it is highly
prevalent in the field and has emerged as a standard of
care in this domain [10].
Intervention description {11a}
The intervention, the IBH-PC toolkit, is a set of imple-
mentation strategies consisting of four components:
1) An online educational curriculum,
2) A structured, team-based, practice redesign and im-
plementation workbook,
3) Remote QI coaching services for internal QI
facilitators, and
4) An online learning community.
The purpose of the IBH-PC toolkit is to guide and
support primary care practices through a practice
change process as they work to increase their degree of
behavioral health integration through, for example,
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improvement of screening, case identification, manage-
ment, or follow-up. Progress through the toolkit and use
of its components are expected to be variable among
participating practices, taking from 9 to 24months.
Online education curriculum The IBH-PC toolkit in-
cludes an asynchronous online curriculum on evidence-
based concepts of IBH and methods of applying them.
The curriculum includes one interprofessional course
for all practice member roles and seven individual
courses, targeting different practice member roles (prac-
tice manager, BHP, PCP, nurse, staff, IBH-PC facilitator)
Courses take approximately 4–14 h to complete, de-
pending on the practice member role. The online cur-
riculum is housed at the Arizona State University and is
made available through an online learning management
platform [30]. It is intended, but not required, that all
practice members complete the courses appropriate for
their roles.
Practice redesign and implementation workbook The
redesign and implementation process is available as a
workbook format (.pdf format) that is posted in an
online, shared workspace. Practices are encouraged to
establish interdisciplinary project teams, with a practice
member serving as project leader and an on-site, internal
facilitator. The workbook directs the project team
through four stages: study start up and leadership
engagement, planning the scope and boundaries of
workflow redesign using a Lean Management approach
[31–33], redesigning workflow with recommended tac-
tics, and implementing those changes in the practice. It
is intended, but not required, that the project teams
complete all stages sequentially.
Remote quality improvement coaching To support the
project teams through the redesign process, external QI
coaches work with individual practices. Each study
practice is assigned a team of two coaches who meet
with them via phone or web-meeting throughout the
practice redesign process (up to 24months). The remote
QI coaches are part of the research team based at the
University of Vermont (UVM). It is intended, but not re-
quired, that all project teams meet with their coaches on
a regular basis.
Online learning community The IBH-PC toolkit in-
cludes an online forum and learning community created
using an open source bulletin board system [34]. It pro-
vides a platform for practice members and other IBH-
PC stakeholders to communicate with one another. Dis-
cussion topics vary and are primarily focused on practice
member needs and interests. It is intended, but not re-
quired, that all project teams engage in the online
learning community through regular participation by at
least one team member.
Criteria for discontinuing or modifying allocated
interventions {11b}
Study practices randomly assigned to the intervention
are encouraged to use the IBH-PC toolkit completely
and sequentially, as prescribed. However, practices may
use the toolkit out of sequence, modify sections, or skip
them completely. Given the low risk of this practice-
level intervention, there are no early stopping rules.
Strategies to improve adherence to interventions {11c}
The IBH-PC toolkit is designed to encourage practice
adherence to the intervention through engagement with
a remote QI coaching team, access to continuing
education credits as part of the online education curricu-
lum, and creating a sense of community with standards
of normal behavior through the online learning
community.
Relevant concomitant care permitted or prohibited during
the trial {11d}
Participating practices may not participate in other
practice change projects similar to the IBH-PC toolkit
during the trial. However, they may use QI and other
strategies to improve any aspect of their practice they
see fit, including improving BH services.
Provisions for post-trial care {30}
Not applicable. The study represents a 24-month prac-
tice level-intervention, there is no need for post-trial
care.
Outcomes {12}
Research question 1: does using the IBH-PC toolkit, a
practice-level intervention, affect patient-centered outcomes
in adult patients with multiple chronic medical and
behavioral health conditions?
Primary outcomes
 Change in mean patient Patient-Reported Outcomes
Measurement Information System [35] (PROMIS-
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Secondary outcomes
 Change in other mean patient-reported measures
of health and quality of care from baseline to
follow-up.
 Empathy [36]
 Medication adherence [37]
 Healthcare utilization [38]
 Time lost due to disability [39]
 Physical function [40]
 Patient centeredness
 Change in mean measures of patient disease control




 Asthma symptoms [43, 44]
 Substance use disorder [45]
 Problem drinking [46]
Research question 2: does using the IBH-PC toolkit affect
the degree of practice-level behavioral health care
integration in primary care practices?
Secondary outcomes
 Change in median PIP total score from baseline to
follow-up







 Workspace Arrangement and Infrastructure
Research question 3: what factors support or impede
successful integration of behavioral health care into
primary care practices?
Secondary outcomes
 Identification of practice characteristics and external
factors supporting or impeding integration as
measured by changes in PIP scores.
Research question 4: what are the costs of implementing
the IBH-PC toolkit?
Secondary outcomes
 Total estimated costs of using the IBH-PC toolkit
over a period of 24 months, excluding the costs and
revenues associated with ongoing clinical operations.
Participant timeline {13} Practices are screened on a
rolling basis for study eligibility and will therefore have
varying randomization and study start dates. Moreover,
it is anticipated that practices will move through the
IBH-PC toolkit at different rates. Therefore, the time-
frames represented in Fig. 2 are anticipated averages
across all study practices.
Sample size {14}
Sample size calculations were adjusted for the cluster
randomized design [47]. To achieve a nominal
significance level of 0.05 for the main hypothesis that
any one or more of the eight PROMIS primary
outcomes achieves significance, we will apply the
Bonferroni correction [48] requiring P < 0.05/8 =
0.00625. All PROMIS domain scales are normalized to a
standard deviation of 10 points [35]. We assume that the
within-practice correlations of the PROMIS scales are
0.03 (similar to the SF-12 [49]). Although minimally im-
portant differences [50] are not fully specified, they
range from 2 to 8 points for other instruments in the
PROMIS series [51, 52].
Power calculations were conducted prior to study
recruitment assuming 75 subjects from 40 practices,
giving the study 3000 subjects and 90% power to detect
a difference in any of the 8 PROMIS scales of 2.5 points
or more. With 45 practices recruited, 43 practices
randomized to intervention or control, and 2 practices
considered as “Vanguard” the study recruitment meets
these power and sample size expectations.
Recruitment {15}
Recruitment of primary care practices to participate in
the study leverages the professional networks of the
study’s leadership and co-investigator teams. Study lead-
ership calls potential practices, screening for interest and
eligibility.
To recruit study patient participants, the DARTNet
Institute identifies potential eligible patients using
electronic medical record data from each practice. The
data extract contains information on patient visits,
medications, and diagnoses. These data retrospectively
span at least 24 months and include dates within 12
months of the study start date. Eligible patients are
contacted by mail and/or phone with an invitation to
participate in the study.
We cannot sample from the entire practice panel of
potentially eligible patients because, in most cases, the
practices have many more patients with multiple chronic
medical and behavioral health conditions than their
BHPs can reasonably support, which would limit our
ability to capture the effects of each practice’s case
finding and clinical management changes on study
outcomes. Nor can we allow each practice to know
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exactly who the consented patient participants are
because the practice may tend to concentrate behavioral
health resources on those patients in a way not usual in
real-world practices, introducing bias. Therefore, we de-
veloped a “Community Panel” for each practice consist-
ing of a random subset of the entire practice’s patient
population of active adult patients (group A in Fig. 3).
Within the Community Panel, some patients will have
the target medical and behavioral conditions and be eli-
gible for to participate in the study (group B). The study
subjects (group C) are recruited from group B. Because
practice change efforts to integrate behavioral health
care usually involve increasing the workload of BHPs,
the Community Panel size is proportional to the number
of BHPs in the practice, approximately 1000 adults per
1.0 full-time equivalent BHP. The Community Panel al-
lows us to conduct a pragmatic trial within the staffing
constraints imposed by real-world conditions.
All practices receive the names of the patients who
comprise their Community Panel during the baseline
Fig. 2 Study timeline
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period of the study, but they are not told which ones are
eligible for the study or which consented to participate.
Control practices may choose to use the Community
Panel in the course of their usual care. Active practices
are encouraged to focus their redesign efforts (pertaining
to screening, case identification, management, follow-up,
etc.) on the patients in the Community Panel.
Approximately 8 participating practices will be
purposefully selected for inclusion in a qualitatively-
driven collective case study of factors that support or
impede successful integration of behavioral health and
primary care (research question 3). We will identify tiers
of “high change” and “low change” practices, where
change is defined as the difference between baseline and
midpoint median PIP total scores. Practices will be re-
cruited on a rolling basis as midpoint PIP scores become
available. Site selection will be informed by emerging
findings from both the qualitative data and successive
phases of quantitative data that are slated to continue
throughout the project period [53].
To estimate the costs of using the IBH-PC toolkit (re-
search question 4), approximately 8 active practices will
be recruited using a combination of purposeful and con-
venience sampling. Selection will be based on practice
type, size, location, and capacity to participate in data
collection activities. Recruitment and data collection will
begin while practices are actively engaged with the IBH-
PC toolkit (these sites need not be those selected for the
qualitative analysis of research question 3.) The cost
analysis was limited to 8 representative practices, in
order to minimize data collection burden and optimize
response.
Assignment of interventions: allocation
Sequence generation {16a}
Eligible practices are assigned to the active or control
arm using a stratified, randomized, approach, in blocks
of 4. Randomization blocks are developed using R [54].
Practices are stratified based on degree of behavioral
health integration at baseline (total PIP score < 50th
percentile vs. total PIP score > =50th percentile) and
geographical area.
Concealment mechanism {16b}
Randomization cards are a dark color, in order to
prevent transparency, and individually sealed in opaque
manila envelopes. Randomization envelopes are shuffled
within block, numbered sequentially within strata and
stored in a locked file cabinet. Potential subversion is
guarded against by storing the randomization envelopes
in a locked file cabinet and only accessing the envelopes
Fig. 3 Patient participants identification schematic
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when at least two members of the study team are
present.
Implementation {16c}
When a practice is deemed eligible and ready to be
randomized, a data analyst determines which stratum
they belong to and opens the next randomization
envelope within that stratum. She writes the practice’s
name and date of randomization on the card, and then
initials the card before filing it. The site’s randomization
status is communicated to the Principal Investigator (PI)
who sends an email to the practice and notifies the
study Practice Change team.
Assignment of interventions: blinding
Who will be blinded {17a}
Once a study practice has been randomized, their
assigned study arm is not blinded. Practices are blinded
as to who the patient participants are within their
practice.
Procedure for unblinding if needed {17b}
Not applicable. This study is an unblinded, practice-level
intervention.
Data collection and management
Plans for assessment and collection of outcomes {18a}
The main source of outcomes data and descriptors are
the patients and practices themselves. On-line surveys
are collected and managed using the Research Electronic
Data Capture (REDCap) system, a secure, web-based ap-
plication designed to support data capture for research
studies [55]. We also offer patients the option of com-
pleting the forms by telephone with a trained interviewer
using a scripted interview, or via paper using a mail-in
option. Outcome measures are collected at three time-
points: baseline, midpoint, and follow-up. The baseline
period reflects the first 0–12months of participation
after randomization, midpoint is 9–12months after
baseline, and follow-up is 18–21months after baseline.
The Data and Analysis Team reviews all records for po-
tential errors.
Study instruments Research question 1: does using the
IBH-PC toolkit, a practice-level intervention, affect
patient-centered outcomes in adults with multiple
chronic medical and behavioral health conditions?
Our primary outcome, the PROMIS-29 [35], is a set of
person-centered measures of physical, mental, emo-
tional, and social health included in the National Insti-
tute of Health’s (NIH) measurement toolbox. Rather
than a disease-focused measurement system, it provides
valid measures of Physical Function, Anxiety, Depres-
sion, Fatigue, Sleep Disturbance, Social Functioning, and
Pain. These aspects of functioning and well-being are
relevant across many chronic conditions and broadly
represent “health-related quality of life.”
Additional instruments will be used to collect
secondary outcomes:
 The Consultation and Relational Empathy [36]
(CARE) survey is a 10-item validated self-report
measure that assesses patients’ perception of pro-
vider empathy. The CARE has been shown to have
excellent reliability (Cronbach’s alpha 0.92).
 The Modified Self-reported Medication-taking Scale
[37] is the Morisky Green Levine Scale (MGLS) four-
item self-report measure assessing adherence to pre-
scription medication. The MGLS has been shown to
have adequate reliability (Cronbach alpha = 0.61 [56]).
 The Utilization Patient Report [38] is a 3-item self-
report measure asking patients to recall their health-
care utilization in the past year. Specifically, patients
are asked to report utilization of visits to the emer-
gency room, overnights in the hospital, and out-
patient appointments to a healthcare provider.
 Time loss due to disability will be measured using
the Restricted Activity Days survey [57]. This survey
asks patients to report on the restriction of their
daily lives due to illness and disability.
 Physical function will be measured using the Duke
Activity Status Index [40] (DASI), a 12-item vali-
dated self-report measurement used to assess func-
tional capacity. The DASI has been shown to have
good to excellent reliability in several studies (Cron-
bach’s alpha ranging from 0.80 to 0.93 [58]) and cor-
relates with peak oxygen uptake measured by
exercise stress test.
 Patient-centered primary care will be measured
using the Patient Centered Index (PCI), a 16-item
questionnaire. This tool was developed for use in the
IBH-PC study by a team of researchers, patients,
and other stakeholders to assess how a patient per-
ceives their care. Reliability and validation measures
are not yet available.
 The 7-item Generalized Anxiety Disorder Scale [42]
(GAD-7) is a self-report questionnaire developed and
validated in a larger primary care patient sample to as-
sess anxiety symptom severity. The GAD-7 has been
shown to have excellent reliability in several studies
(Cronbach’s alpha ranging from 0.79 to 0.91 [59]).
 The 9-item Patient Health Questionnaire [41]
(PHQ-9) is a validated self-report measure of de-
pression symptom severity. The PHQ-9 has shown
to have good reliability (Cronbach’s alpha ranging
from 0.86 to 0.89 [41]). Recognizing the sensitive na-
ture of the questions on the PHQ-9 concerning
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suicidal thoughts and ideation, information on how
to access the national suicide helpline was distrib-
uted with all paper study materials and was pro-
grammed into the electronic survey data capture
system.
 The Asthma Symptom Utility Index [43, 44] (ASUI)
is a 10-item validated self-report measure assessing
control and quality of life as it relates to asthma
symptoms. Reliability for the ASUI is considered
good with a Cronbach’s alpha of 0.74 [43].
 Alcohol use will be assessed using 2-items from the
Self-Report Habit Index-Alcohol [46] (SRHI-A). The
SRHI-A has shown to have excellent reliability
(Cronbach’s alpha 0.94 [46]).
 Substance Use Disorder will be assessed using the 5-
item Substance Disorders subscale of the Global As-
sessment of Individual Needs-Short Screener [45]
(GAIN-SS), a biopsychosocial screener for individ-
uals presenting with substance use and mental
health concerns. The GAIN-SS Substance Use sub-
scale has been shown to have acceptable reliability
(Cronbach’s alpha ranging from 0.77 to 0.84 [60]).
Research question 2: does using the IBH-PC toolkit
affect the degree of practice-level behavioral health care
integration in primary care practices?
The Practice Integration Profile (PIP) is a survey of 30
items completed by primary care providers and staff
about their own practice [26, 27]. It provides a total
integration score and 6 domain scores: practice
workflow, clinical services, integration methods, case
identification, patient engagement, and workspace
arrangement and infrastructure.
Research question 3: what factors support or impede
successful integration of behavioral health care into
primary care practices?
A cross-case comparative analysis [53, 61, 62] will be
conducted in selected practices. Researchers will collect
data contained in field notes, such as observations of the
physical layout of the practice, workflow, and practice
meetings; transcripts of semi-structured interviews with
coaches, cluster leaders, and practice staff; and relevant
site documents.
Research question 4: what are the costs of
implementing the IBH-PC toolkit?
A dedicated staff member from each of selected active
study sites will periodically complete an in-depth pro-
gram implementation Cost Assessment Tool (CAT).
The CAT is a role-based time-effort evaluation instru-
ment listing the number and type of practice staff par-
ticipating in each toolkit activity. We will total the time
various practice members engage with each component
of the IBH-PC toolkit over a 24-month period and
calculate the time-effort and cost in US dollars using
median total compensation rates appropriate for the
practice’s ZIP code and the practice staff’s professional
roles. We will also include any supply, equipment, cap-
ital, or other non-personnel costs, including training
time and coaching time associated with toolkit imple-
mentation. Time-effort data collected from participating
practices by each participant and subtask will be ana-
lyzed for completeness, range and “face validity” of time
estimates, and appropriateness of data to determine
econometric outcomes. Key variables will then be esti-
mated from global and sub-group averages, including
total time and corresponding cost of program imple-
mentation steps, time/cost of the planning phase, and
those of all implementation phases.
Plans to promote participant retention and complete
follow-up {18b}
First, each practice receives financial support for a
clinical leader and a practice manager to attend to data
collection and other non-clinical (research-related) as-
pects of the project. Second, practice sites are organized
into clusters of about 5–7 practices. Each cluster has a
designated local Cluster PI (a behavioral or medical pro-
vider or researcher). The Cluster PI serves as a member
of the research team and coordinates research activities,
engages upper practice management, and provides li-
aison with the investigators. Third, all control practices
have access to the intervention (the IBH-PC toolkit)
upon completion of the follow-up assessments.
To encourage patient participants to remain engaged
and complete the baseline and follow-up surveys, we in-
clude a midpoint survey data collection time point to
minimize the time in between research contacts and pay
patient participants $30 upon completion of each survey
($90 total).
Data management {19}
The research team developed a written data governance
policy to guide appropriate storage and use of study
data. Data from consented patient participants are
collected electronically, on paper, and over the phone.
To complete baseline, midpoint, and follow-up patient
surveys, the study team contacts patient participants by
each of these three methods over a 3-month period until
a response is received or the 3-month window is
reached. The following steps are taken:
 All patient participants with email addresses are
emailed at week zero.
 Three email reminders are sent every other day if
there is no response.
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 At week one, a paper survey is sent to the patient
participant’s mailing address.
 At week five, a second batch of emails is sent
followed by two phone calls 1 week later. If the
patient participant cannot be reached via phone, a
voicemail is left.
 At week eight, a second paper mailer is sent to
patient participants who have yet to respond.
 At weeks nine through twelve, two more emails and
two more phone calls are attempted before
concluding efforts.
Data collected electronically via REDCap are
automatically captured and stored in REDCap.
Trained research assistants sort and enter paper
surveys into REDCap and then they are filed and
stored in a locked filing cabinet inside a locked office.
Postal address, email, and phone number are verified
for accuracy and updated as need. Phone surveys are
conducted by trained research assistants and
information is entered directly into REDCap. Patient
participants who submitted surveys with missing data
are contacted by telephone to complete the survey.
Double data entry is performed, by a team of trained
research assistants, on a randomly selected subset of
10% of the surveys received for each time point
(baseline, midpoint, and follow-up). If the data entry
error rate is greater than 0.05%, the entire batch of
surveys is re-entered.
Confidentiality {27}
Data from EMRs used to recruit patient subjects are
extracted, transformed, loaded and curated from clinical
practice sites by the DARTNet Institute. DARTNet uses
a HIPAA-compliant sFTP cloud transfer system. This in-
cludes encryption of all data in transit and deletion of
the data as soon as the transfer is complete. Data files
transferred to DARTNet are immediately moved behind
a second firewall where access is internet protocol ad-
dress (IP)-to-IP controlled. All file manipulations occur
behind this second firewall. Once DARTNet has com-
pleted subject recruitment, they use a similar system,
Egnyte [63], to transfer the list of patients on a practice’s
Community Panel to a practice.
Patient names, medical record numbers, and other
unique identifiers are stripped and replaced with a
unique study identifier before transferring EMR files to
the UVM research team. Electronic medical record files
contain data on healthcare visits, clinical measures
including blood pressure and hemoglobin A1C, as well
as medication and problem lists. Only research
personnel authorized to access data for the proposed
project have access to the data.
After transfer of EMR data to UVM, all source
material, copies, data files, transcripts, and other
research materials are maintained in a secure
environment with access restricted to members of the
study Data and Analysis Team.
Online patient and practice surveys are collected and
managed using the REDCap system [55], a secure, web-
based application designed to support data capture for
research studies.
Physical copies of any patient surveys or other research
documents with potentially identifying information are
kept under lock and key. Digital materials are secured
behind password-protected firewalls.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Not applicable. Biological specimens are not collected as
part of this study.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Research question 1: does using the IBH-PC toolkit, a
practice-level intervention, affect patient-centered out-
comes in adults with multiple chronic medical and be-
havioral health conditions?
For the primary outcomes, we will use generalized
linear mixed (GLM) models [64] of patient health status
(PROMIS-29 scales) to perform intention-to-treat ana-
lyses [65] as a function of experimental condition (active
vs. control) and patient characteristics, with patients
clustered within practices. The parameters of interest
are the central tendency (mean), statistical significance
(P values), and 95% confidence intervals (CI) of the ad-
justed change in PROMIS-29 domain from baseline to
follow-up. Each of the 8 outcome domains in the
PROMIS-29 will be modeled individually as 8 separate
hypotheses with adjustment for multiple comparisons
and for clustering within practices.
Patient characteristics will be measured at baseline
and will include age, gender, race, ethnicity, marital
status, employment, education, and income.
For secondary patient outcomes, including change in
other patient-reported measures of health and quality of
care, and measures of patient disease control from base-
line to follow-up, we will use similar GLM models as
above but will not adjust for multiple comparisons.
Research question 2: does using the IBH-PC toolkit affect
the degree of practice-level behavioral health care
integration in primary care practices?
We will use GLM models of practice integration level
(total PIP and PIP domains) to perform intention-to-
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treat analyses as a function of experimental condition
(active vs. control) and practice characteristics. The pa-
rameters of interest are the central tendency (median),
statistical significance (P values) and 95% CI of the
change in total PIP and PIP domains from baseline to
follow-up.
Practice characteristics will be measured at baseline
and will include ownership type, specialty, training
status, non-profit status, size, region, census-tract based
variables, primary care medical home (PCMH) status,
and % Medicare patients.
Research question 3: what factors support or impede
successful integration of behavioral health care into
primary care practices?
A cross-case comparative analysis [53, 61, 62] will be
conducted for selected case study practices. Practices
will be selected from the extremes of change in the main
outcome variable, and additional practices maybe se-
lected for confirming/disconfirming analyses [66]. Data
collected from the individual case study sites will be ana-
lyzed to identify site-specific contextual factors that sup-
port or impede integration. Through multiple rounds of
coding the data, researchers will organize and categorize
related evidence on a topic from multiple data sources,
assisting with pattern identification in preparation for
thematic analysis [62, 67].
After analysis at the individual practice level, a cross-
case study analysis will be conducted to identify promin-
ent themes. This process allows for the in-depth examin-
ation of the individual practice sites to be followed by a
cross-cutting analysis of integration processes. Findings
will include themes and insights regarding the factors
that supported or impeded successful integration of be-
havioral health care across the selected practices.
Research question 4: what are the costs of implementing
the IBH-PC toolkit?
Descriptive statistical and basic econometrical (i.e., time/
effort-cost estimation) methods will be used to
summarize findings. Costs of IBH-PC toolkit implemen-
tation will be measured only, while research costs
(identifying eligible patients, collecting and analyzing re-
search data, etc.) and changes in operational costs and
revenues after completion of the intervention will not be
included.
Interim analyses {21b}
Not applicable. Interim analyses and stopping guidelines
are not planned for this study due to the low risk nature
of the practice-level intervention.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
Subgroup analyses
Subgroup analyses will be conducted to understand if
the IBH-PC toolkit is more or less effective for various
patient and practice groups. Specific patient subgroups
to be tested include gender, age in quartiles, race (white
vs. other), education (less than high school graduation,
high school diploma, college degree), degree of multi-
morbidity (2 vs. > 2 qualifying conditions), and each of
the qualifying conditions.
Specific practice subgroups will be analyzed based on
practice size, staffing, geography, and financial structure.
These subgroup analyses will follow the same plan as
the primary analysis except that an additional
characteristic (representing subgroup membership) will
be included as well as its interaction with the
experimental condition.
Exploratory analyses
We will replace the binary predictor variable (active vs.
control) with continuous variables (the PIP total score
and its subscales) to answer the question: What is the
relationship between a practice’s degree of behavioral
health care integration and patient-centered outcomes?
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
We will employ the “intention-to-treat” principle;
analyses will be conducted according to a practice’s
randomization assignment. The final analysis population
will be fully described and differences from the enrolled
population will be presented. An advantage of GLM
models with time of measurement as an explicit
covariate is that equal numbers of data points and
equally spaced intervals between data points are not
required [68], so subjects without complete data still
contribute to the analysis. Cases that are lost may
remain in the analysis, although they will provide less
information and reduce the variance of estimated effects
less than cases that are present for all measurement
times.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The study is registered on ClinicalTrials.gov
(NCT02868983). A complete, cleaned, de-identified copy
of the final dataset used in conducting the final analyses
will be made available within 1 year of study completion.
It will include a data dictionary with response options
and missing values defined as well as a complete set of
survey instruments (excluding copyright-protected ma-
terial not licensed for transfer). The data will be available
as an Stata data set or comma-separated file. We will
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not make data from qualitative results available because
of the potential for identifying individuals. Despite
redacting interviewees’ names from their transcripts,
there remains potential for identification by other infor-
mation shared throughout the interviews. This is par-
ticularly relevant given our focus on contextual factors,
which necessarily include information about the practice
and surrounding community. We concluded that it
would not be feasible to determine all of the potentially
identifiable data that would need to be redacted to pro-
tect the identity of interviewees.
Outside investigators who wish to use the data may
request them from the PI. They will be encouraged to
collaborate with the research team as appropriate. If the
research question they propose is not already under
analysis by a member of the research team, the data will
be encrypted and sent via SFTP or other secure transfer
protocol. If outside investigators wish to reproduce any
of our analyses, a full description of our methods
(including statistical programming scripts in Stata) as
well as consultation by the PI, statistical investigators or
others as appropriate, will be made available.
Outside investigators will be required to follow all the
protocols for confidentiality, security, notifications to the
study sponsor (PCORI), acknowledgments of funding,
etc. required of the research team.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
The research team includes expertise in behavioral and
medical management, research design, multicenter data
collection, epidemiology and biostatistics, patient
engagement, practice transformation, continuing
education, quantitative outcomes assessment, and
qualitative analysis of processes and outcomes. The team
also includes several patients and other stakeholders
from the multiple chronic conditions community who
provide expertise from lived experience.
Composition of the data monitoring committee, its role and
reporting structure {21a}
The Data and Safety Monitoring Board (DSMB) is an
independent group that advises the IBH-PC study inves-
tigators. The members of the DSMB serve in an individ-
ual capacity and provide their expertise and
recommendations. They report to the PI.
The primary responsibilities of the DSMB are to (1)
periodically review and evaluate reports of potential
adverse events reported by study participants, personnel,
or others; (2) determine the causality and severity of
adverse events; and (3) make recommendations for
changes in study protocols, operations, or consent
procedures as a result of their findings. The DSMB
considers study-specific data as well as relevant back-
ground knowledge of the patient population under
study.
The chair of the DSMB is a patient. Additional
members include a PCP, a Psychiatrist, and a BHP.
The DSMB meets at least annually and whenever the
PI determines that a significant number of adverse
events have been reported or a single adverse event
report is potentially serious and warrants DSMB review.
Adverse event reporting and harms {22}
Although the intervention is low risk, it is possible that a
research participant could suffer an unanticipated or
adverse event related to the study. If such a concern is
raised by study staff, a participant, an investigator,
clinician, or any other party, the event is reported to the
Institutional Review Board (IRB) and reviewed by the
DSMB.
The DSMB determines the causality of each adverse
event as “unrelated,” “related,” or “possibly related” to
the IBH-PC toolkit or other aspects of the study. It de-
termines the severity of each adverse event according to
the Common Terminology Criteria for Adverse Events
[69] (CTCAE). Recommendations for changes in the
consent process or study protocol may be made, based
on the nature of the adverse event.
Frequency and plans for auditing trial conduct {23}
There are no plans for auditing trial conduct.
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
Changes to the study protocol are communicated to all
research team members electronically and reviewed in
accordance with IRB policies. Through regular meetings
with the study sponsor (PCORI), changes are discussed
and tracked through a regular milestone reporting
process.
Dissemination plans {31a}
Dissemination is a standing agenda item for the
Investigators and the Stakeholder Advisory Group
(SAG). Research team and SAG members, as well as
clinicians and patients at the clinical sites, may be asked
to make presentations to health care providers,
accountable care organizations (ACO), primary care
organizations, health-related agencies, legislative com-
mittees, and business forums (employer and payer orga-
nizations) in their communities. Patient advisors will be
asked to review all materials so that findings are under-
standable and usable by a broad audience. It is antici-
pated that study findings will be reported in numerous
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formats such as peer-reviewed literature, conference
proceedings, blog posts, and policy briefs.
Discussion
As IBH gains momentum and primary care practices are
encouraged to provide integrated behavioral health
services, evidence-based interventions that are shown to
effectively increase practice integration levels will be im-
portant. This study evaluates the effectiveness of an
evidence-based practice change intervention to improve
patient outcomes in a vulnerable population and to in-
crease a practice’s degree of integration. There are a
number of strengths to our design. First, we are able to
overcome a major obstacle in the study of integrated
versus co-located practices by randomizing all practices
and using co-location as the control condition. Second,
we will be able to understand the impact of the IBH-PC
toolkit on multiple domains of health and practice inte-
gration. Third, our patient recruiting procedure uses a
trusted third party to consent patients so practices can
remain blind to their patients’ participation status -- an
important feature that reduces biases as practices apply
newly-learned care approaches with their patients. Fi-
nally, the pragmatic nature of the intervention is a
strength, as it provides flexibility in how the IBH-PC
toolkit is used and which components of integration a
practice chooses to apply at any given time.
The pragmatic study design is also a limitation in that
it will be difficult to ascertain which aspects of the
intervention are associated with any potential improved
outcomes. However, supporting flexibility in how and
when practices engage with the intervention is
important for practice retention, and we will be able to
examine which components of the IBH-PC toolkit are
most vs. least commonly used by individual practices.
Another study limitation is that, due to the complexity
of longitudinal EMR extraction across multiple sites, we
will not evaluate the impact of the intervention on
physiologic outcomes such as blood pressure and
hemoglobin A1C.
The study will provide both clinical trial and
contextual information that is vital to efforts to
improve the integration of behavioral and primary
medical care [70, 71].
Trial status
The IBH-PC study information is available on Clinical-
Trials.gov, protocol version 4, April 16, 2019. Practice
recruitment began when the study was funded on April
1, 2016. Currently, 45 primary care practices have been
recruited for study participation. Two of these practices
are participating as “Vanguard” (pilot) sites and are not
contributing data to the main analyses. One practice
withdrew from the study, leaving 42 participating
practices. Twenty of these practices are randomized to
the active arm and 22 to the control arm.
Patient participant recruitment began in September
2017. Currently, there are 3006 patient participants who
have completed baseline surveys and may be eligible for
the main analyses if they complete follow-up surveys.
Follow-up data collection concluded in December 2020.
Data processing is underway.
Eight IBH-PC active practices have been recruited for
inclusion in the qualitative case study analysis focused
on examining factors associated with supporting or im-
peding behavioral health integration and data collection
is complete. For the cost assessment analysis, 8 IBH-PC
active practices were been recruited and data collection
is complete. Recruitment and data collection were com-
pleted in December 2020.
Due to the complex nature of the study intervention
and potential need to respond with modifications, the
study team chose to submit the protocol for publication
near the conclusion of the follow-up data collection
period in order to ensure accuracy in the reported
details.
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